Molecular Partners Ag (MOLN) Net Cash Flow (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Net Cash Flow of -$23577.3 for Q1 2026, down 220.57% year-on-year from $19554.5 in Q1 2025, and down 100.09% on a QoQ basis from $25.2 million in Q4 2025.
Molecular Partners Ag (MOLN) Net Cash Flow (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Net Cash Flow for 7 consecutive years, with -$23577.3 the latest figure, recorded in Q1 2026.
- Quarterly Net Cash Flow fell 220.57% year-over-year to -$23577.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (up 607.47% YoY) and the FY2025 annual result came in at $25.2 million, up 610.0% from the prior year.
- Net Cash Flow retreated to -$23577.3 in Q1 2026 per MOLN's latest filing, from $25.2 million in the prior quarter.
- Over the last five years, Net Cash Flow for MOLN reached as high as $42.5 million in Q2 2022 and fell as low as -$42.5 million in Q3 2022.
- A 5-year average of $1.1 million and a median of $300.17 in 2024 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 6414.49% in 2025 against a maximum downside of 906.76% in 2025.
- Year by year, Net Cash Flow stood at $16.5 million in 2022, then sank by 206.12% to -$17.5 million in 2023, then jumped by 71.76% to -$4.9 million in 2024, then jumped by 609.73% to $25.2 million in 2025, then plunged by 100.09% to -$23577.3 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$23577.3, $25.2 million, and -$24.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -23,577.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,577.34 |
| Mar 31, 2026 | -23,577.34 |
| Dec 31, 2025 | 25.18 Mn |
| Dec 31, 2025 | 25.18 Mn |
| Sep 30, 2025 | -23.99 Mn |
| Sep 30, 2025 | -23.99 Mn |
| Jun 30, 2025 | 23.18 Mn |
| Jun 30, 2025 | 23.18 Mn |
| Mar 31, 2025 | 19,554.48 |
| Mar 31, 2025 | 19,554.48 |
| Dec 31, 2024 | -4.94 Mn |
| Dec 31, 2024 | -4.94 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | -2.85 Mn |
| Jun 30, 2024 | -2.85 Mn |
| Mar 31, 2024 | 300.17 |
| Mar 31, 2024 | 300.17 |
| Dec 31, 2023 | -17.49 Mn |
| Dec 31, 2023 | -17.49 Mn |